PVLA vs ADMA
Side-by-side comparison of price performance, valuation, growth, profitability, analyst targets and technical trend.
PVLA · Palvella Therapeutics$175.92 ▲ 12.16%
ADMA · ADMA Biologics$12.73 ▼ 3.63%
One year, rebased to 100
Each line starts at 100 so growth is directly comparable
- PVLA +119.1%
- ADMA -13.5%
Head to head
| Metric | PVLA | ADMA |
|---|---|---|
| Price | $175.92 | $12.73 |
| Change today | ▲ 12.16% | ▼ 3.63% |
| Market cap | $2.57B | $2.82B |
| Return, 3 months | +15.6% | +30.6% |
| Return, year to date | +68.1% | -30.2% |
| Return, 1 year | +126.0% | -12.3% |
| P/E (TTM) | – | 16.5 |
| P/B | 13.0 | 6.4 |
| P/E percentile vs own 5y | 24th | 66th |
| Dividend yield | – | – |
| Revenue growth (YoY, latest qtr) | – | +2.0% |
| Net profit growth (YoY) | -130.9% | +10.5% |
| Gross margin | – | 64.7% |
| Operating margin | – | 42.3% |
| Net margin | – | 33.0% |
| Return on equity | -46.6% | 41.9% |
| Analyst target vs. price | +31.7% | +17.8% |
| Analyst buy share | 100% | 50% |
| RSI (14) | 73 | 66 |
| 30-day volatility | 66.4% | 79.8% |
| Max drawdown, 1 year | -31.1% | -62.7% |
| Trend read | Strong uptrend | Strong uptrend |
| Analyst consensus | Buy | Buy |
Green cells mark the best value in each row where "better" is clear-cut (lower P/E, higher margin). That is a reading of the numbers, not a recommendation. Financials are in each company's reporting currency.
What the numbers say
- ADMA is the largest of the group by market value.
- PVLA has returned the most over the past year.
- PVLA has been the calmest stock over the last 30 days.